Constipation Drug Clears Depression Brain Fog in Clinical Trial
A week-long course of prucalopride improved memory, attention, and thinking speed in people with depression history.
Summary
Researchers at the University of Birmingham found that prucalopride, a licensed constipation drug, improved cognitive function in adults with a history of depression. In a small randomized trial of 50 participants, those who took the drug for 7–10 days performed better on memory, attention, and thinking speed tests compared to placebo. The drug targets the 5-HT4 serotonin receptor in both the gut and brain, offering a potential new pathway for treating depression-related brain fog. Participants were not on antidepressants and had been in remission for at least six months. No significant side effects were reported, making this a promising candidate for drug repurposing in cognitive symptoms of depression.
Detailed Summary
Depression is widely known for its emotional toll, but cognitive symptoms — memory lapses, poor concentration, and mental fog — often persist long after mood improves. These lingering deficits affect daily functioning and quality of life, yet they remain an undertreated feature of the illness. Researchers are now pointing to a surprising candidate for addressing this gap: a common constipation drug.
A clinical trial led by Dr. Angharad de Cates at the University of Birmingham, published in Psychological Medicine, tested prucalopride in 50 adults who had previously experienced depression but were in remission and off medication. Participants took either 2mg of prucalopride or a placebo for 7–10 days. Those on the drug responded faster and more accurately on a battery of cognitive tests covering declarative memory, working memory, executive function, and emotional processing.
Prucalopride works by activating the 5-HT4 serotonin receptor, which is expressed in both the gut and the brain. This dual presence makes it a biologically plausible tool for influencing brain function. The gut-brain axis has attracted growing research interest, and this study adds evidence that gut-targeting drugs can produce measurable cognitive effects.
No significant side effects were observed during the trial. The drug gently stimulates bowel motility at its licensed dose, making it well-tolerated even over the short treatment window. This safety profile strengthens the case for further investigation and potential repurposing.
Despite the promising results, the trial was small and involved participants already in remission — meaning the findings may not directly apply to people currently in a depressive episode. Larger, longer studies in diverse populations are needed before any clinical recommendations can be made. Still, the research opens an intriguing avenue: targeting the 5-HT4 receptor pathway to develop or repurpose drugs that address the cognitive dimension of depression.
Key Findings
- Prucalopride (2mg/day for 7–10 days) improved memory, attention, and thinking speed vs. placebo in depression history patients.
- The drug targets the 5-HT4 serotonin receptor present in both the gut and brain, linking gut-brain signaling to cognition.
- No significant side effects were reported, supporting its tolerability for potential cognitive use.
- Cognitive brain fog persists in depression even after mood recovers, representing a major unmet treatment need.
- Findings support investigating 5-HT4-targeting drugs for repurposing in depression and other mental health conditions.
Methodology
This is a research summary based on a peer-reviewed randomized controlled trial published in Psychological Medicine, a credible journal. The study was conducted by University of Birmingham and Oxford researchers with NIHR support. The trial was small (n=50) and short-term, limiting generalizability.
Study Limitations
The sample size of 50 is small and participants were already in remission, so results may not apply to active depression. The treatment window of 7–10 days is insufficient to assess long-term cognitive benefits or risks. Independent replication in larger, more diverse populations is needed before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: